Formycon AG provided earnings guidance for the year 2023. For the year, the company expects a significant increase of revenues compared to fiscal 2022, resulting from revenue and earnings contributions from the commercialization of the Lucentis biosimilar (FYB201) Ranivisio^3/Ongavia^4 /CIMERLI^5 as well as anticipated milestone payments for the FYB202 project.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.48 EUR | +3.07% | +3.01% | -21.10% |
Apr. 25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.10% | 821M | |
+23.37% | 47.02B | |
+50.13% | 41.86B | |
-0.94% | 41.76B | |
-4.32% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- FYB Stock
- News Formycon AG
- Formycon AG Provides Earnings Guidance for the Year 2023